Poll: U.S. Voters Want PBM and Insurance Reform—And Strong Biotech

Why It Matters

The poll reveals bipartisan demand for concrete drug‑price reforms, signaling political risk for MFN proposals and creating an opening for policies that target supply‑chain mark‑ups while preserving biotech innovation.

Key Takeaways

• 80% favor reforms targeting PBMs, insurers, 340B program
• 88% support direct rebates and lower co‑pays for patients
• 90% want a thriving U.S. biotech sector
• Insurance costs rank third after housing, groceries
• Bipartisan support challenges Most Favored Nation approach

Pulse Analysis

The BIO survey underscores a growing voter backlash against opaque drug‑pricing mechanisms. Respondents identified health‑insurance premiums as a top financial pressure, second only to housing and groceries, and blamed PBMs and insurers for siphoning roughly half of every drug dollar. By quantifying this frustration, the poll gives policymakers a clear mandate: reforms must cut middle‑man fees, increase price transparency, and deliver savings directly to the point of sale. Such measures resonate across the political spectrum, suggesting that any legislative effort lacking concrete consumer‑focused provisions will struggle to gain traction.

For lawmakers, the data presents a strategic dilemma. While the Most Favored Nation (MFN) model—intended to cap drug prices by referencing foreign benchmarks—has attracted bipartisan interest, the poll shows voters quickly lose support once they understand its potential to curb innovation and fail to address the root causes of high out‑of‑pocket costs. Instead, proposals that force PBMs to pass negotiated discounts to patients, tighten 340B program oversight, and lower co‑pays align more closely with public sentiment. This creates an opening for incremental, supply‑chain‑focused legislation that can be marketed as both cost‑saving and innovation‑friendly.

The biotech sector stands to benefit from this consumer‑driven narrative. A strong domestic industry is viewed as essential for delivering breakthrough therapies, and voters’ 90% endorsement signals continued political backing for research incentives and funding. Companies that can demonstrate pricing transparency and patient‑centric value propositions will likely enjoy a competitive edge, especially as insurers and PBMs adapt to tighter regulatory expectations. Stakeholders should therefore prioritize collaborative pricing models that balance affordability with sustained investment in R&D, positioning themselves as partners in the broader goal of accessible, innovative healthcare.